# EDGAR Filing Document

**Accession Number:** 0001935476
**File Stem:** 0001213900-26-062378
**Filing Date:** 2026-5
**Character Count:** 9299
**Document Hash:** 25ceb577f9efaf15f7e11addd554ee82
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-062378.hdr.sgml**: 20260528

**ACCESSION NUMBER**: 0001213900-26-062378

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260528

**DATE AS OF CHANGE**: 20260528

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Quantum Computing Inc.
- **CENTRAL INDEX KEY:** 0001758009
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-PREPACKAGED SOFTWARE [7372]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 824533053
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-90765
- **FILM NUMBER:** 261038780

**BUSINESS ADDRESS:**
- **STREET 1:** 5 MARINE VIEW PLZ, SUITE 214
- **CITY:** HOBOKEN
- **STATE:** NJ
- **ZIP:** 07030
- **BUSINESS PHONE:** 703-436-2161

**MAIL ADDRESS:**
- **STREET 1:** 5 MARINE VIEW PLZ, SUITE 214
- **CITY:** HOBOKEN
- **STATE:** NJ
- **ZIP:** 07030
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Huang Yuping
- **CENTRAL INDEX KEY:** 0001935476

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** 815 BLANCH AVENUE
- **CITY:** NORWOOD
- **STATE:** NJ
- **ZIP:** 07648

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 2)**

**Quantum Computing Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.0001 per share**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**Christopher Roberts**<br>5 Marine View Plaza, Suite 214<br>Hoboken NJ 07030<br>(703) 436-2121

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**04/03/2023**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Yuping Huang** | Name of reporting person<br>**Yuping Huang** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**23302068.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**23302068.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**23302068.00** | Aggregate amount beneficially owned by each reporting person<br>**23302068.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**10.33%** | Percent of class represented by amount in Row (11)<br>**10.33%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.0001 per share

**(b) Name of Issuer:**
Quantum Computing Inc.

**(c) Address of Issuer's Principal Executive Offices:**
5 Marine View Plaza, Suite 214, Hoboken, NJ, 07030

**Item 4. Purpose of Transaction**

Except as described in this Item 4, Dr. Huang has no present plans or proposals that relate to or would result in any of the matters set forth in subparagraphs (a)-(j) of Item 4 of Form Schedule 13D. Dr. Huang reserves the right, in light of his future evaluation of the Issuer's financial condition, business, operations and prospects, the market price of the Common Stock, conditions in the securities markets generally, general economic and industry conditions and other relevant factors, to change his plans and intentions at any time and from time to time, as he deems appropriate.

In his capacity as a director and senior executive officer of the Issuer, Dr. Huang participates in deliberations of the Issuer's senior management and directors in the normal course of the Issuer's business that could involve any of the matters set forth in subparagraphs (a)-(j) of the instructions to Item 4 from time to time, and, consistent with his fiduciary duties as an officer, may make proposals or recommendations to the Issuer's board of directors that could involve such matters from time to time.

In addition, as a member of the Issuer's senior management, Dr. Huang participates in Issuer compensatory plans, including plans pursuant to which awards of equity securities are made (including, from time to time, to Dr. Huang), in the ordinary course of business, generally on an annual basis.

**Item 5. Interest in Securities of the Issuer**

**(a)**
As of the date hereof, Dr. Huang beneficially owns 23,302,068 shares of Common Stock (the "Huang Common Shares"), representing 10.33% of the total issued and outstanding shares of Common Stock as of the date hereof.1 These consist of:

(i) 23,953,706 shares of Common Stock issued at the closing of the merger with QPhoton, less 4,200,000 shares sold or donated, plus 83,200 shares received as a bonus;

(ii) 1,050,812 shares of Common Stock issued upon conversion of the Warrants;

(iii) 314,350 shares of Common Stock underlying options to purchase 314,350 shares of Common Stock, which are fully vested; and

(iv) 2,000,000 shares of Common Stock owned by the YH Family Trust of 2025, of which Dr. Huang's wife serves as trustee.

(b) Dr. Huang holds sole voting and dispositive power over the Huang Common Shares.

(c) Other than disclosed above, there were no transactions by Dr. Huang in the Issuer's Common Stock during the last 60 days.

(d) No other person is known to have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, the Huang Common Shares.

(e) Not applicable.

1 Based on 225,594,497 shares of Common Stock issued and outstanding as of may 20, 2026 (as reported in the Issuer's definitive proxy statement filed on April 30, 2026), and the 414,350 shares of Common Stock underlying the vested options issued to the reporting person.

**(b)**
—

**(c)**
—

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Dr. Huang has an employment agreement (the "First Employment Agreement") with the Issuer which includes options to purchase 400,000 shares of Common Stock, vesting in four annual equal installments beginning at the date of grant October 14, 2022. Of such options, 100,000 vested immediately upon grant, and 100,000 vested on each of the 12-month, 24-month and 36-month anniversaries of the date of grant, such that all 400,000 options are now fully vested. The First Employment Agreement also provides that upon Dr. Huang's termination without Cause or resignation for Good Reason (each as defined in the First Employment Agreement), all stock options granted by the Issuer and then held by Dr. Huang shall be accelerated and become fully vested and exercisable as of the date of such termination. The First Employment Agreement was replaced by an amended and restated employment agreement with the Issuer effective January 1, 2026 (the "Second Employment Agreement"), which provides that Dr. Huang is eligible for annual long-term incentive awards of stock and stock options in amounts and subject to terms and conditions to be determined by the Board and based on performance criteria to be established by the Board. The Second Employment Agreement also provides that upon Dr. Huang's termination without Cause or resignation for Good Reason, all stock options granted by the Issuer and then held by Dr. Huang shall be accelerated and become fully vested and exercisable as of the date of such termination. To date, no securities of the Issuer have been granted to Dr. Huang under the Second Employment Agreement. Other than such employment agreements, to the knowledge of Dr. Huang, there are no other contracts, arrangements, understandings or relationships (legal or otherwise) between Dr. Huang and/or any other person, with respect to any securities of the Issuer.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Yuping Huang

**Signature:** /s/ Yuping Huang

**Name/Title:** Dr. Yuping Huang

**Date:** 05/28/2026